|Date and Time||Title|
|Sep 6, 2022|
4:00pm - 4:40pm (Pacific)
|To Have and Have Not - A Closer Look at the Data for Biologics With - and Without - MTX in PsA|
This is a Non-CME/CE presentation.
Sponsored by Lilly Medical
A chronic, inflammatory musculoskeletal disease, psoriatic arthritis (PsA) can lead to damaged joints, impaired physical function, and decreased quality of life among affected individuals. Despite advances in treatment, the heterogenous nature of PsA makes disease management challenging. A growing understanding of the immunopathogenesis of PsA has led to the development of biologic therapies that target Tumor Necrosis Factor, JAK, IL-23, and IL-17. When using these biologic therapies, there remains debate as to whether there is benefit in continuing MTX treatment. New data from recent studies have sought to address this question and suggest that concomitant use of biologics with MTX does not necessarily result in increased efficacy across different disease domains.
Join Drs Ogdie, Wright, and Sebba as they review the data, evaluate the role of concomitant use of biologics with MTX, and discuss evidence-based strategies to improve patient outcomes.
|Sep 8, 2022|
2:50pm - 3:25pm (Pacific)
|Session I: Non-CME/CE Presentation|
2:50 PM PT | Withdrawing Therapies From Patients in Remission